A moderately low phosphate intake may provide health benefits analogous to those conferred by UV light - A further advantage of vegan diets

Medical Hypotheses

Volumn 61, Issue 5-6, 2003, Pages 543-560

  McCarty, M F ^a  

^a Pantox Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; PARATHYROID HORMONE; VITAMIN D;

ARTICLE; AUTOCRINE EFFECT; AUTOIMMUNITY; BIOAVAILABILITY; BIOSYNTHESIS; BLOOD VESSEL; BONE DENSITY; CANCER RISK; COLON CANCER; DIET SUPPLEMENTATION; DOWN REGULATION; HORMONAL REGULATION; HUMAN; HYPERTENSION; IMMUNOREGULATION; KIDNEY; LIGHT EXPOSURE; PARATHYROID HORMONE RELEASE; PHOSPHATE INTAKE; PRIORITY JOURNAL; PROPHYLAXIS; SKIN DEFECT; ULTRAVIOLET RADIATION; UPREGULATION; VEGETARIAN DIET;

EID: 0242635847     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(03)00228-7     Document Type: Article

References (292)

1. Holick M. F. McCollum Award Lecture, 1994: vitamin D - new horizons for the 21st century. Am J Clin Nutr 1994; 60: 619-630.
2. Garland C. F., Garland F. C. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980; 9: 227-231.
3. Garland F. C., Garland C. F., Gorham E. D., Young J. F. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 1990; 19: 614-622.
4. Gorham E. D., Garland F. C., Garland C. F. Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 1990; 19: 820-824.
5. Garland C. F., Garland F. C., Gorham E. D. Can colon cancer incidence and death rates be reduced calcium with and vitamin D? Am J Clin Nutr 1991; 54: 193S-201S.
6. Lefkowitz E. S., Garland C. F. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol 1994; 23: 1133-1136.
7. Schwartz G. G., Hulka B. S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990; 10: 1307-1311.
8. Hanchette C. L., Schwartz G. G. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992; 70: 2861-2869.
9. Luscombe C. J., Fryer A. A., French M. E., Liu S., Saxby M. F., Jones P. W. et al. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 2001; 358: 641-642.
10. Luscombe C. J., French M. E., Liu S., Saxby M. F., Jones P. W., Fryer A. A. et al. Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br J Cancer 2001; 85: 1504-1509.
11. Ainsleigh H. G. Beneficial effects of sun exposure on cancer mortality. Prev Med 1993; 22: 132-140.
12. Studzinski G. P., Moore D. C. Sunlight - can it prevent as well as cause cancer? Cancer Res 1995; 55: 4014-4022.
13. McCarty M. F. Parathyroid hormone may be a cancer promoter - an explanation for the decrease in cancer risk associated with ultraviolet light, calcium, and vitamin D. Med Hypotheses 2000; 54: 475-482.
14. Grant W. B. An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. Cancer 2002; 94: 272-281.
15. Grant W. B. An estimate of premature cancer mortality in the United States due to inadequate dose of solar ultraviolet-B radiation, a source of vitamin D. Cancer 2002; 94: 1867-1875.
16. Rostand S. G. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997; 30: 150-156.
17. Rostand S. G. Seasonal changes in blood pressure in patients undergoing hemodialysis. N Engl J Med 1999; 340: 965-966.
18. Hayes C. E., Cantorna M. T., DeLuca H. F. Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med 1997; 216: 21-27.
19. Cantorna M. T. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med 2000; 223: 230-233.
20. Embry A. F., Snowdon L. R., Vieth R. Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000; 48: 271-272.
21. Luscombe C. J., Fryer A. A., French M. E., Liu S., Saxby M. F., Jones P. W. et al. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 2001; 358: 641-642.
22. Luscombe C. J., French M. E., Liu S., Saxby M. F., Jones P. W., Fryer A. A. et al. Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br J Cancer 2001; 85: 1504-1509.
23. Garland C. F., Comstock G. W., Garland F. C., Helsing K. J., Shaw E. K., Gorham E. D. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989; 2: 1176-1178.
24. Braun M. M., Helzlsouer K. J., Hollis B. W., Comstock G. W. Colon cancer and serum vitamin D metabolite levels 10-17 years prior to diagnosis. Am J Epidemiol 1995; 142: 608-611.
25. Tangrea J., Helzlsouer K., Pietinen P., Taylor P., Hollis B., Virtamo J. et al. Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men. Cancer Causes Control 1997; 8: 615-625.
26. Ahonen M. H., Tenkanen L., Teppo L., Hakama M., Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000; 11: 847-852.
27. Corder E. H., Guess H. A., Hulka B. S., Friedman G. D., Sadler M., Vollmer R. T. et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993; 2: 467-472.
28. Braun M. M., Helzlsouer K. J., Hollis B. W., Comstock G. W. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 1995; 6: 235-239.
29. Gann P. H., Ma J., Hennekens C. H., Hollis B. W., Haddad J. G., Stampfer M. J. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996; 5: 121-126.
30. Nomura A. M., Stemmermann G. N., Lee J., Kolonel L. N., Chen T. C., Turner A. et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998; 9: 425-432.
31. Janowsky E. C., Lester G. E., Weinberg C. R., Millikan R. C., Schildkraut J. M., Garrett P. A. et al. Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr 1999; 2: 283-291.
32. Krause R., Buhring M., Hopfenmuller W., Holick M. F., Sharma A. M. Ultraviolet B and blood pressure. Lancet 1998; 352: 709-710.
33. Brennan P. J., Greenberg G., Miall W. E., Thompson S. G. Seasonal variation in arterial blood pressure. Br Med J (Clin Res Ed) 1982; 285: 919-923.
34. Woodhouse P. R., Khaw K. T., Plummer M. Seasonal variation of blood pressure and its relationship to ambient temperature in an elderly population. J Hypertens 1993; 11: 1267-1274.
35. Fujiwara T., Kawamura M., Nakajima J., Adachi T., Hiramori K. Seasonal differences in diurnal blood pressure of hypertensive patients living in a stable environmental temperature. J Hypertens 1995; 13: 1747-1752.
36. Kristal-Boneh E., Harari G., Green M. S., Ribak J. Summer-winter variation in 24 h ambulatory blood pressure. Blood Press Monit 1996; 1: 87-94.
37. Keen H., Ekoe J. M. The geography of diabetes mellitus. Br Med Bull 1984; 40: 359-365.
38. Li X. H., Li T. L., Yang Z., Liu Z. Y., Wei Y. D., Jin S. X. et al. A nine-year prospective study on the incidence of childhood type 1 diabetes mellitus in China. Biomed Environ Sci 2000; 13: 263-270.
39. Garancini P., Callus G., Calori G., Formigaro F., Micossi P. Incidence and prevalence rates of diabetes mellitus in Italy from routine data: a methodological assessment. Eur J Epidemiol 1991; 7: 55-63.
40. Anon. Vitamin D supplement in early childhood and risk for type I (insulin-dependent) drabetes mellitus. The EURODIAB Substudy 2 Study Group. Diabetologia 1999; 42: 51-54.
41. Hypponen E., Laara E., Reunanen A., Jarvelin M. R., Virtanen S. M. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358: 1500-1503.
42. Vieth R. The mechanisms of vitamin D toxicity. Bone Miner 1990; 11: 267-272.
43. Chesney R. W., Zimmerman J., Hamstra A., DeLuca H. F., Mazees R. B. Vitamin D metabolite concentrations in vitamin D deficiency. Are calcitriol levels normal. Am J Dis Child 1981; 135: 1025-1028.
44. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999; 69: 842-856.
45. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001; 22: 477-501.
46. Chapuy M. C., Arlot M. E., Duboeuf F., Brun J., Crouzet B., Arnaud S. et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327: 1637-1642.
47. Dawson-Hughes B., Harris S. S., Krall E. A., Dallal G. E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-676.
48. Bischoff H. A., Stahelin H. B., Urscheler N., Ehrsam R., Vonthein R., Perrig-Chiello P. et al. Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 1999; 80: 54-58.
49. Prabhala A., Garg R., Dandona P. Severe myopathy associated with vitamin D deficiency in western New York. Arch Intern Med 2000; 160: 1199-1203.
50. Verhaar H. J., Samson M. M., Jansen P. A., de Vreede P. L., Manten J. W., Duursma S. A. Muscle strength, functional mobility and vitamin D in older women. Aging (Milano) 2000; 12: 455-460.
51. Pfeifer M., Begerow B., Minne H. W., Schlotthauer T., Pospeschill M., Scholz M. et al. Vitamin D status, trunk muscle strength, body sway, falls, and fractures among 237 postmenopausal women with osteoporosis. Exp Clin Endocrinol Diabetes 1902; 109: 87-92.
52. Zamboni M., Zoico E., Tosoni P., Zivelonghi A., Bortolani A., Maggi S. et al. Relation between vitamin D, physical performance, and disability in elderly persons. J Gerontol A Biol Sci Med Sci 2002; 57: M7-M11.
53. Pfeifer M., Begerow B., Minne H. W., Abrams C., Nachtigall D., Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000; 15: 1113-1118.
54. Kristoffersson A., Bostrom A., Soderberg T. Muscle strength is improved after parathyroidectomy in patients with primary hyperparathyroidism. Br J Surg 1992; 79: 165-168.
55. Colliander E. B., Strigard K., Westblad P., Rolf C., Nordenstrom J. Muscle strength and endurance after surgery for primary hyperparathyroidism. Eur J Surg 1998; 164: 489-494.
56. Deutch S. R., Jensen M. B., Christiansen P. M., Hessov I. Muscular performance and fatigue in primary hyperparathyroidism. World J Surg 2000; 24: 102-107.
57. Miller G. J. Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Metastasis Rev 1998; 17: 353-360.
58. van den Bemd G. J., Pols H. A., van Leeuwen J. P. Antitumor effects of 1,25-dihydroxyvitamin D3 and vitamin D analogs. Curr Pharm Des 2000; 6: 717-732.
59. Friedrich M. Vitamin D and breast cancer: new approaches for hormonal therapy of breast cancer. Clin Exp Obstet Gynecol 2000; 27: 77-82.
60. Zhao X. Y., Feldman D. The role of vitamin D in prostate cancer. Steroids 2001; 66: 293-300.
61. Hansen C. M., Binderup L., Hamberg K. J., Carlberg C. Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci 2001; 6: D820-D848.
62. Bortman P., Folgueira M. A., Katayama M. L., Snitcovsky I. M., Brentani M. M. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells: a mini review. Braz J Med Biol Res 2002; 35: 1-9.
63. Guyton K. Z., Kensler T. W., Posner G. H. Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol 1902; 41: 421-442.
64. Oikawa T., Hirotani K., Ogasawara H., Katayama T., Nakamura O., Iwaguchi T. et al. Inhibition of angiogenesis by vitamin D3 analogues. Eur J Pharmacol 1990; 178: 247-250.
65. Shokravi M. T., Marcus D. M., Alroy J., Egan K., Saornil M. A., Albert D. M. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 1995; 36: 83-87.
66. Majewski S., Skopinska M., Marczak M., Szmurlo A., Bollag W., Jablonska S. Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. J Investig Dermatol Symp Proc 1996; 1: 97-101.
67. Fujioka T., Hasegawa M., Ishikura K., Matsushita Y., Sato M., Tanji S. Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. J Urol 1998; 160: 247-251.
68. Iseki K., Tatsuta M., Uehara H., Iishi H., Yano H., Sakai N. et al. Inhibition of angiogenesis as a mechanism for inhibition by 1 alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 1999; 81: 730-733.
69. Mantell D. J., Owens P. E., Bundred N. J., Mawer E. B., Canfield A. E. 1alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000; 87: 214-220.
70. Schwartz G. G., Whitlatch L. W., Chen T. C., Lokeshwar B. L., Holick M. F. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 1998; 7: 391-395.
71. Tangpricha V., Flanagan J. N., Whitlatch L. W., Tseng C. C., Chen T. C., Holt P. R. et al. 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet5213R 2001; 357: 1673-1674.
72. Barreto A. M., Schwartz G. G., Woodruff R., Cramer S. D. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 2000; 9: 265-270.
73. Hsu J. Y., Feldman D., McNeal J. E., Peehl D. M. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 2001; 61: 2852-2856.
74. Holt P. R., Arber N., Halmos B., Forde K., Kissileff H., McGlynn K. A. et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev 2002; 11: 113-119.
75. Juppner H., Abou-Samra A. B., Freeman M., Kong X. F., Schipani E., Richards J. et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991; 254: 1024-1026.
76. Abou-Samra A. B., Juppner H., Force T., Freeman M. W., Kong X. F., Schipani E. et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormane-reteted peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sci USA 1992; 89: 2732-2736.
77. Offermanns S., Iida-Klein A., Segre G. V., Simon M. I. G alpha q family members couple parathyroid hormone (PTH)/PTH-related peptide and calcitonin receptors to phospholipase C in COS-7 cells. Mol Endocrinol 1996; 10: 566-574.
78. Takasu H., Guo J., Bringhurst F. R. Dual signaling and ligand selectivity of the human PTH/PTHrP receptor. J Bone Miner Res 1999; 14: 11-20.
79. Rankin W., Grill V., Martin T. J. Parathyroid hormone-related protein and hypercalcemia. Cancer 1997; 80: 1564-1571.
80. Rabbani S. A. Molecular mechanism of action of parathyroid hormone related peptide in hypercalcemia of malignancy: therapeutic strategies (review). Int J Oncol 2000; 16: 197-206.
81. Strewler G. J. The parathyroid hormone-related protein. Endocrinol Metab Clin North Am 2000; 29: 629-645.
82. Iddon J., Bundred N. J., Hoyland J., Downey S. E., Baird P., Salter D. et al. Expression of parathyroid hormone-related protein and its receptor in bone metastases from prostate cancer. J Pathol 2000; 191: 170-174.
83. Luparello C., Birch M. A., Gallagher J. A., Burtis W. J. Clonal heterogeneity of the growth and invasive response of a human breast carcinoma cell line to parathyroid hormone-related peptide fragments. Carcinogenesis 1997; 18: 23-29.
84. Downey S. E., Hoyland J., Freemont A. J., Knox F., Walls J., Bundred N. J. Expression of the receptor for parathyroid hormone-related protein in normal and malignant breast tissue. J Pathol 1997; 183: 212-217.
85. Carron J. A., Fraser W. D., Gallagher J. A. PTHrP and the PTH/PTHrP receptor are co-expressed in human breast and colon tumours. Br J Cancer 1997; 76: 1095-1098.
86. Birch M. A., Carron J. A., Scott M., Fraser W. D., Gallagher J. A. Parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor expression and mitogenic responses in human breast cancer cell lines. Br J Cancer 1995; 72: 90-95.
87. Iwamura M., Abrahamsson P. A., Foss K. A., Wu G., Cockett A. T., Deftos L. J. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 1994; 43: 675-679.
88. Cataisson C., Lieberherr M., Cros M., Gauville C., Graulet A. M., Cotton J. et al. Parathyroid hormone-related peptide stimulates proliferation of highly tumorigenic human SV40-immortalized breast epithelial cells. J Bone Miner Res 2000; 15: 2129-2139.
89. Esbrit P., Benitez-Verguizas J., de Miguel F., Valin A., Garcia-Ocana A. Characterization of parathyroid hormone/parathyroid hormone-related protein receptor and signaling in hypercalcemic Walker 256 tumor cells. J Endocrinol 2000; 166: 11-20.
90. Iezzoni J. C., Bruns M. E., Frierson H. F., Scott M. G., Pence R. A., Deftos L. J. et al. Coexpression of parathyroid hormone-related protein and its receptor in breast carcinoma: a potential autocrine effector system. Mod Pathol 1998; 11: 265-270.
91. Yoshida M., Ohtsuru A., Samejima T., Okazaki M., Fujishita A., Ito M. et al. Involvement of parathyroid hormone-related peptide in cell proliferation activity of human uterine leiomyomas. Endocr J 1999; 46: 81-90.
92. Dougherty K. M., Blomme E. A., Koh A. J., Henderson J. E., Pienta K. J., Rosol T. J. et al. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res 1999; 59: 6015-6022.
93. Falzon M., Du P. Enhanced growth of MCF-7 breast cancer cells overexpressing parathyroid hormone-related peptide. Endocrinology 2000; 141: 1882-1892.
94. Farr H. W., Fahey T. J. J., Nash A. G., Farr C. M. Primary hyperparathyroidism and cancer. Am J Surg 1973; 126: 539-543.
95. Falzon M. DNA sequences in the rat parathyroid hormone-related peptide gene responsible for 1,25-dihydroxyvitamin D3-mediated transcriptional repression. Mol Endocrinol 1996; 10: 672-681.
96. Kremer R., Sebag M., Champigny C., Meerovitch K., Hendy G. N., White J. et al. Identification and characterization of 1,25-dihydroxyvitamin D3-responsive repressor sequences in the rat parathyroid hormone-related peptide gene. J Biol Chem 1996; 271: 16310-16316.
97. Falzon M., Zong J. The noncalcemic vitamin D analogs EB1089 and 22-oxacalcitriol suppress serum-induced parathyroid hormone-related peptide gene expression in a lung cancer cell line. Endocrinology 1998; 139: 1046-1053.
98. Abe M., Akeno N., Ohida S., Horiuchi N. Inhibitory effects of 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid on parathyroid hormone-related protein expression by oral cancer cells (HSC-3). J Endocrinol 1998; 156: 349-357.
99. Hanson A. S., Linas S. L. Parathyroid hormone/adenylate cyclase coupling in vascular smooth muscle cells. Hypertension 1994; 23: 468-475.
100. Okano K., Wu S., Huang X., Pirola C. J., Juppner H., Abou-Samra A. B. et al. Parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor and its messenger ribonucleic acid in rat aortic vascular smooth muscle cells and UMR osteoblast-like cells: cell-specific regulation by angiotensin-II and PTHrP. Endocrinology 1994; 135: 1093-1099.
101. Ishikawa M., Akishita M., Kozaki K., Toba K., Namiki A., Yamaguchi T. et al. Amino-terminal fragment (1-34) of parathyroid hormone-related protein inhibits migration and proliferation of cultured vascular smooth muscle cells. Atherosclerosis 1998; 136: 59-66.
102. Jiang B., Morimoto S., Yang J., Niinoabu T., Fukuo K., Ogihara T. Expression of parathyroid hormone/parathyroid hormone-related protein receptor in vascular endothelial cells. J Cardiovasc Pharmacol 1998; 31(suppl. 1): S142-S144.
103. Isales C. M., Sumpio B., Bollag R. J., Zhong Q., Ding K. H., Du W. et al. Functional parathyroid hormone receptors are present in an umbilical vein endothelial cell line. Am J Physiol Endocrinol Metab 2000; 279: E654-E662.
104. Schleiffer R., Xue H., McCarron D. A., Bukoski R. D. Effect of chronic and subacute parathyroidectomy on blood pressure and resistance artery contractility in the spontaneously hypertensive rat. J Hypertens 1993; 11: 709-716.
105. Schleiffer R. Involvement of parathyroid hormone (PTH) in genetic models of hypertension. J Endocrinol Invest 1992; 15: 87-95.
106. Kishimoto H., Tsumura K., Fujioka S., Uchimoto S., Morii H. Chronic parathyroid hormone administration reverses the antihypertensive effect of calcium loading in young spontaneously hypertensive rats. Am J Hypertens 1993; 6: 234-240.
107. Hulter H. N., Melby J. C., Peterson J. C., Cooke C. R. Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens 1986; 2: 360-370.
108. Fliser D., Franek E., Fode P., Stefanski A., Schmitt C. P., Lyons M. et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant 1997; 12: 933-938.
109. Lind L., Wengle B., Wide L., Sorensen O. H., Ljunghall S. Hypertension in primary hyperparathyroidism - reduction of blood pressure by long-term treatment with vitamin D (alphacalcidol). A double-blind, placebo-controlled study. Am J Hypertens 1988; 1: 397-402.
110. Lind L., Wengle B., Lithell H., Ljunghall S. Plasma ionized calcium and cardiovascular risk factors in mild primary hyperparathyroidism: effects of long-term treatment with active vitamin D (alphacalcidol). J Intern Med 1992; 231: 427-432.
111. Sancho J. J., Rouco J., Riera-Vidal R., Sitges-Serra A. Long-term effects of parathyroidectomy for primary hyperparathyroidism on arterial hypertension. World J Surg 1992; 16: 732-735.
112. Raine A. E., Bedford L., Simpson A. W., Ashley C. C., Brown R., Woodhead J. S. et al. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 1993; 43: 700-705.
113. Nilsson I. L., Aberg J., Rastad J., Lind L. Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery 1999; 126: 1049-1055.
114. Kosch M., Hausberg M., Vormbrock K., Kisters K., Gabriels G., Rahn K. H. et al. Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. Cardiovasc Res 2000; 47: 813-818.
115. Lundgren E., Lind L., Palmer M., Jakobsson S., Ljunghall S., Rastad J. Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. Surgery 2001; 130: 978-985.
116. Lind L., Wengle B., Wide L., Ljunghall S. Reduction of blood pressure during long term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. Am J Hypertens 1989; 2: 20-25.
117. Lewanczuk R. Z., Benishin C. G., Shan J., Pang P. K. Clinical aspects of parathyroid hypertensive factor. J Cardiovasc Pharmacol 1994; 23(suppl. 2): S23-S26.
118. Resnick L. M., Lewanczuk R. Z., Laragh J. H., Pang P. K. Parathyroid hypertensive factor-like activity in human essential hypertension: relationship to plasma renin activity and dietary salt sensitivity. J Hypertens 1993; 11: 1235-1241.
119. Pang P. K., Benishin C. G., Shan J., Lewanczuk R. Z. PHF: the new parathyroid hypertensive factor. Blood Press 1994; 3: 148-155.
120. Krylova S. M., Pang P. K., Shan J., Lewanczuk R. Z., Benishin C. G. Quantitative determination of parathyroid hypertensive factor by enzyme-linked immunosorbent assay. Am J Hypertens 2000; 13: 1173-1179.
121. Keatinge W. R., Donaldson G. C. Cardiovascular mortality in winter. Arctic Med Res 1995; 54(suppl. 2): 16-18.
122. van Rossum C. T., Shipley M. J., Hemingway H., Grobbee D. E., Mackenbach J. P., Marmot M. G. Seasonal variation in cause-specific mortality: are there high-risk groups? 25-year follow-up of civil servants from the first Whitehall study. Int J Epidemiol 2001; 30: 1109-1116.
123. van der Bom J. G., de Maat M. P., Bots M. L., Hofman A., Kluft C., Grobbee D. E. Seasonal variation in fibrinogen in the Rotterdam Study. Thromb Haemost 1997; 78: 1059-1062.
124. Frohlich M., Sund M., Russ S., Hoffmeister A., Fischer H. G., Hombach V. et al. Seasonal variations of rheological and hemostatic parameters and acute-phase reactants in young, healthy subjects. Arterioscler Thromb Vasc Biol 1997; 17: 2692-2697.
125. Crawford V. L., Sweeney O., Coyle P. V., Halliday I. M., Stout R. W. The relationship between elevated fibrinogen and markers of infection: a comparison of seasonal cycles. Quart J Med 2000; 93: 745-750.
126. Mavri A., Guzic-Salobir B., Salobir-Pajnic B., Keber I., Stare J., Stegnar M. Seasonal variation of some metabolic and haemostatic risk factors in subjects with and without coronary artery disease. Blood Coagul Fibrinol 2001; 12: 359-365.
127. Mitnick M. A., Grey A., Masiukiewicz U., Bartkiewicz M., Rios-Velez L., Friedman S. et al. Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. Am J Physiol Endocrinol Metab 2001; 280: E405-E412.
128. Heinrich P. C., Castell J. V., Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636.
129. Grey A., Mitnick M. A., Masiukiewicz U., Sun B. H., Rudikoff S., Jilka R. L. et al. A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology 1999; 40: 4683-4690.
130. Radeff J. M., Nagy Z., Stern P. H. Involvement of PKC-beta in PTH, TNF-alpha, and IL-1 beta effects on IL-6 promoter in osteoblastic cells and on PTH-stimulated bone resorption. Exp Cell Res 2001; 268: 179-188.
131. Grey A., Mitnick M. A., Shapses S., Ellison A., Gundberg C., Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption - a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3450-3454.
132. Ridker P. M. Novel risk factors and markers for coronary disease. Adv Intern Med 2000; 45: 391-413.
133. Prager R., Schernthaner G., Niederle B., Roka R. Evaluation of glucose tolerance, insulin secretion, and insulin action in patients with primary hyperparathyroidism before and after surgery. Calcif Tissue Int 1990; 46: 1-4.
134. Kautzky-Willer A., Pacini G., Niederle B., Schernthaner G., Prager R. Insulin secretion, insulin sensitivity and hepatic insulin extraction in primary hyperparathyroidism before and after surgery. Clin Endocrinol (Oxf) 1992; 37: 147-155.
135. Kumar S., Olukoga A. O., Gordon C., Mawer E. B., France M., Hosker J. P. et al. Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clin Endocrinol (Oxf) 1994; 40: 47-53.
136. Richards M. L., Thompson N. W. Diabetes mellitus with hyperparathyroidism: another indication for parathyroidectomy? Surgery 1999; 126: 1160-1166.
137. Taylor W. H., Khaleeli A. A. Coincident diabetes mellitus and primary hyperparathyroidism. Diabetes Metab Res Rev 2001; 17: 175-180.
138. Kautzky-Willer A., Pacini G., Barnas U., Ludvik B., Streli C., Graf H. et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 1995; 47: 200-206.
139. Begum N., Sussman K. E., Draznin B. Calcium-induced inhibition of phosphoserine phosphatase in insulin target cells is mediated by the phosphorylation and activation of inhibitor 1. J Biol Chem 1992; 267: 5959-5963.
140. Akmal M., Perkins S., Kasim S. E., Oh H. Y., Smogorzewski M., Massry S. G. Verapamil prevents chronic renal failure-induced abnormalities in lipid metabolism. Am J Kidney Dis 1993; 22: 158-163.
141. Massry S. G., Fadda G. Z. Chronic renal failure is a state of cellular calcium toxicity. Am J Kidney Dis 1993; 21: 81-86.
142. Ni Z., Smogorzewski M., Massry S. G. Effects of parathyroid hormone on cytosolic calcium of rat adipocytes. Endocrinology 1994; 135: 1837-1844.
143. Zemel M. B., Shi H., Greer B., Dirienzo D., Zemel P. C. Regulation of adiposity by dietary calcium. FASEB J 2000; 14: 1132-1138.
144. Dent P., Lavoinne A., Nakielny S., Caudwell F. B., Watt P., Cohen P. The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. Nature 1990; 348: 302-308.
145. Begum N., Draznin B. Effect of streptozotocin-induced diabetes on GLUT-4 phosphorylation in rat adipocytes. J Clin Invest 1992; 90: 1254-1262.
146. Reusch J. E., Begum N., Sussman K. E., Draznin B. Regulation of GLUT-4 phosphorylation by intracellular calcium in adipocytes. Endocrinology 1991; 129: 3269-3273.
147. Begum N., Leitner W., Reusch J. E., Sussman K. E., Draznin B. GLUT-4 phosphorylation and its intrinsic activity. Mechanism of Ca(2+)-induced inhibition of insulin-stimulated glucose transport. J Biol Chem 1993; 268: 3352-3356.
148. Reusch J. E., Sussman K. E., Draznin B. Inverse relationship between GLUT-4 phosphorylation and its intrinsic activity. J Biol Chem 1993; 268: 3348-3351.
149. Lind L., Pollare T., Hvarfner A., Lithell H., Sorensen O. H., Ljunghall S. Long-term treatment with active vitamin D (alphacalcidol) in middle-aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure. Diabetes Res 1989; 11: 141-147.
150. Scragg R., Holdaway I., Singh V., Metcalf P., Baker J., Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract 1995; 27: 181-188.
151. Lind L., Hanni A., Lithell H., Hvarfner A., Sorensen O. H., Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 1995; 8: 894-901.
152. Baynes K. C., Boucher B. J., Feskens E. J., Kromhout D. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 1997; 40: 344-347.
153. Wareham N. J., Byrne C. D., Carr C., Day N. E., Boucher B. J., Hales C. N. Glucose intolerance is associated with altered calcium homeostasis: a possible link between increased serum calcium concentration and cardiovascular disease mortality. Metabolism 1997; 46: 1171-1177.
154. Chiu K. C., Chuang L. M., Lee N. P., Ryu J. M., McGullam J. L., Tsai G. P. et al. Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism 2000; 49: 1501-1505.
155. Sanchez M., de la Sierra A., Coca A., Poch E., Giner V., Urbano-Marquez A. Oral calcium supplementation reduces intraplatelet free calcium concentration and insulin resistance in essential hypertensive patients. Hypertension 1997; 29: 531-536.
156. Colditz G. A., Manson J. E., Stampfer M. J., Rosner B., Willett W. C., Speizer F. E. Diet and risk of clinical diabetes in women. Am J Clin Nutr 1992; 55: 1018-1023.
157. Arai H., Miyamoto K., Taketani Y., Yamamoto H., Iemori Y., Morita K. et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res 1997; 12: 915-921.
158. Gross C., Eccleshall T. R., Malloy P. J., Villa M. L., Marcus R., Feldman D. The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J Bone Miner Res 1996; 11: 1850-1855.
159. Harris S. S., Eccleshall T. R., Gross C., Dawson-Hughes B., Feldman D. The vitamin D receptor start codon polymorphism (Fold) and bone mineral density in premenopausal American black and white women. J Bone Miner Res 1997; 12: 1043-1048.
160. Gennari L., Becherini L., Mansani R., Masi L., Falchetti A., Morelli A. et al. Fold polymorphism at translation initiation site of the vitamin D receptor gene predicts bone mineral density and vertebral fractures in postmenopausal Italian women. J Bone Miner Res 1999; 14: 1379-1386.
161. Lucotte G., Mercier G., Burckel A. The vitamin D receptor FokI start codon polymorphism and bone mineral density in osteoporotic postmenopausal French women. Clin Genet 1999; 56: 221-224.
162. Kanan R. M., Varanasi S. S., Francis R. M., Parker L., Datta H. K. Vitamin D receptor gene start codon polymorphism (FokI) and bone mineral density in healthy male subjects. Clin Endocrinol (Oxf) 2000; 53: 93-98.
163. Choi Y. M., Jun J. K., Choe J., Hwang D., Park S. H., Ku S. Y. et al. Association of the vitamin D receptor start codon polymorphism (FokI) with bone mineral density in postmenopausal Korean women. J Hum Genet 2000; 45: 280-283.
164. Chiu K. C., Chuang L. M., Yoon C. The vitamin D receptor polymorphism in the translation initiation codon is a risk factor for insulin resistance in glucose tolerant Caucasians. BMC Med Genet EDAT-2001/03/07 10:00 MHDA-2001/03/ 07 10:00 PHST-2001/Jan/06 [received] PHST-2001/Feb/15 [accepted] PHST-2001/Feb/15 [aheadofprint] PST-ppublish 1902;2:2.
165. Gross C., Musiol I. M., Eccleshall T. R., Malloy P. J., Feldman D.
166. Ortlepp J. R., Lauscher J., Hoffmann R., Hanrath P., Joost H. G. The vitamin D receptor gene variant is associated with the prevalence of type 2 diabetes mellitus and coronary artery disease. Diabet Med 2001; 18: 842-845.
167. Morrison N. A., Qi J. C., Tokita A., Kelly P. J., Crofts L., Nguyen T. V. et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367: 284-287.
168. Cooper G. S., Umbach D. M. Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J Bone Miner Res 1996; 11: 1841-1849.
169. Chen H. Y., Chen W. C., Hsu C. D., Tsai F. J., Tsai C. H., Li C. W. Relation of BsmI vitamin D receptor gene polymorphism to bone mineral density and occurrence of osteoporosis in postmenopausal Chinese women in Taiwan. Osteoporos Int 2001; 12: 1036-1041.
170. Dawson-Hughes B., Harris S. S., Finneran S. Calcium absorption on high and low calcium intakes in relation to vitamin D receptor genotype. J Clin Endocrinol Metab 1995; 80: 3657-3661.
171. McClure L., Eccleshall T. R., Gross C., Villa M. L., Lin N., Ramaswamy V. et al. Vitamin D receptor polymorphisms, bone mineral density, and bone metabolism in postmenopausal Mexican-American women. J Bone Miner Res 1997; 12: 234-240.
172. Karkoszka H., Chudek J., Strzelczyk P., Wiecek A., Schmidt-Gayk H., Ritz E. et al. Does the vitamin D receptor genotype predict bone mineral loss in haemodialysed patients. Nephrol Dial Transplant 1998; 13: 2077-2080.
173. Ferrari S., Manen D., Bonjour J. P., Slosman D., Rizzoli R. Bone mineral mass and calcium and phosphate metabolism in young men: relationships with vitamin D receptor allelic polymorphisms. J Clin Endocrinol Metab 1999; 84: 2043-2048.
174. Arnaud J., Constans J. Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet 1993; 92: 183-188.
175. Hirai M., Suzuki S., Hinokio Y., Hirai A., Chiba M., Akai H. et al. Variations in vitamin D-binding protein (group-specific component protein) are associated with fasting plasma insulin levels in Japanese with normal glucose tolerance. J Clin Endocrinol Metab 2000; 85: 1951-1953.
176. Szathmary E. J. The effect of Gc genotype on fasting insulin level in Dogrib Indians. Hum Genet 1987; 75: 368-372.
177. Klupa T., Malecki M., Hanna L., Sieradzka J., Frey J., Warram J. H. et al. Amino acid variants of the vitamin D-binding protein and risk of diabetes in white Americans of European origin. Eur J Endocrinol 1999; 141: 490-493.
178. Ye W. Z., Dubois-Laforgue D., Bellanne-Chantelot C., Timsit J., Velho G. Variations in the vitamin D-binding protein (Gc locus) and risk of type 2 diabetes mellitus in French Caucasians. Metabolism 2001; 50: 366-369.
179. Fliser D., Stefanski A., Franek E., Fode P., Gudarzi A., Ritz E. No effect of calcitriol on insulin-mediated glucose uptake in healthy subjects. Eur J Clin Invest 1997; 27: 629-633.
180. Gravholt C. H., Holck P., Nyholm B., Christiansen E., Erlandsen M., Schmitz O. No seasonal variation of insulin sensitivity and glucose effectiveness in men. Metabolism 2000; 49: 32-38.
181. Armbrecht H. J., Wongsurawat V. J., Hodam T. L., Wongsurawat N. Insulin markedly potentiates the capacity of parathyroid hormone to increase expression of 25-hydroxyvitamin D3-24-hydroxylase in rat osteoblastic cells in the presence of 1,25-dihydroxyvitamin D3. FEBS Lett 1996; 393: 77-80.
182. Ishida H., Seino Y., Tsuda K., Matsukura S., Miyamoto Y., Ishizuka S. et al. Circulating levels of vitamin D metabolites in patients with hyperinsulinaemia. Hum Nutr Clin Nutr 1984; 38: 473-475.
183. Ayesha I., Bala T. S., Reddy C. V., Raghuramulu N. Vitamin D deficiency reduces insulin secretion and turnover in rats. Diabetes Nutr Metab 2001; 14: 78-84.
184. Kumar S., Davies M., Zakaria Y., Mawer E. B., Gordon C., Olukoga A. O. et al. Improvement in glucose tolerance and beta-cell function in a patient with vitamin D deficiency during treatment with vitamin D. Postgrad Med J 1994; 70: 440-443.
185. Boucher B. J., Mannan N., Noonan K., Hales C. N., Evans S. J. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia 1995; 38: 1239-1245.
186. Beaulieu C., Kestekian R., Havrankova J., Gascon-Barre M. Calcium is essential in normalizing intolerance to glucose that accompanies vitamin D depletion in vivo. Diabetes 1993; 42: 35-43.
187. Greenhalgh P. M. Diabetes in British south Asians: nature, nurture, and culture. Diabet Med 1997; 14: 10-18.
188. Boucher B. Diabetes in British South Asians: nature, nurture, and culture. Diabet Med 1997; 14: 707-708.
189. Feskens E. J., Bowles C. H., Kromhout D. Inverse association between fish intake and risk of glucose intolerance in normoglycemic elderly men and women. Diabetes Care 1991; 14: 935-941.
190. Adler A. I., Boyko E. J., Schraer C. D., Murphy N. J. Lower prevalence of impaired glucose tolerance and diabetes associated with daily seal oil or salmon consumption among Alaska Natives. Diabetes Care 1994; 17: 1498-1501.
191. Feskens E. J., Virtanen S. M., Rasanen L., Tuomilehto J., Stengard J., Pekkanen J. et al. Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 1995; 18: 1104-1112.
192. Begum N., Sussman K. E., Draznin B. Calcium-induced inhibition of phosphoserine phosphatase in insulin target cells is mediated by the phosphorylation and activation of inhibitor 1. J Biol Chem 1992; 267: 5959-5963.
193. Fleck A. Latitude and ischaemic heart disease. Lancet 1989; 1: 613-Fleck, A.
194. DeLuca H. F., Cantorna M. T. Vitamin D: its role and uses in immunology. FASEB J 2001; 15: 2579-2585.
195. Adams J. S., Gacad M. A. Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exp Med 1985; 161: 755-765.
196. Dusso A. S., Finch J., Brown A., Ritter C., Delmez J., Schreiner G. et al. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 1991; 72: 157-164.
197. Gyetko M. R., Hsu C. H., Wilkinson C. C., Patel S., Young E. Monocyte 1 alpha-hydroxylase regulation: induction by inflammatory cytokines and suppression by dexamethasone and uremia toxin. J Leukoc Biol 1993; 54: 17-22.
198. Overbergh L., Decallonne B., Valckx D., Verstuyf A., Depovere J., Laureys J. et al. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol 2000; 120: 139-146.
199. Tsoukas C. D., Watry D., Escobar S. S., Provvedini D. M., Dinarello C. A., Hustmyer F. G. et al. Inhibition of interleukin-1 production by 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1989; 69: 127-133.
200. D'Ambrosio D., Cippitelli M., Cocciolo M. G., Mazzeo D., Di Lucia P., Lang R. et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NT-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998; 101: 252-262.
201. Piemonti L., Monti P., Sironi M., Fraticelli P., Leone B. E., Dal Cin E. et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 2000; 164: 4443-4451.
202. Muller K., Bendtzen K. 1,25-Dihydroxyvitamin D3 as a natural regulator of human immune functions. J Invest Dermatol Symp Proc 1996; 1: 68-71.
203. McCarty M. F. Upregulation of lymphocyte apoptosis as a strategy for preventing and treating autoimmune disorders: a role for whole-food vegan diets, fish oil and dopamine agonists. Med Hypotheses 2001; 57: 258-275.
204. Utiger R. D. The need for more vitamin D. N Engl J Med 1998; 338: 828-829.
205. Heaney R. P. Lessons for nutritional science from vitamin D. Am J Clin Nutr 1999; 69: 825-826.
206. Glerup H., Mikkelsen K., Poulsen L., Hass E., Overbeck S., Thomsen J. et al. Commonly recommended daily intake of vitamin D is not sufficient if sunlight exposure is limited. J Intern Med 2000; 247: 260-268.
207. Vieth R., Cole D. E., Hawker G. A., Trang H. M., Rubin L. A. Wintertime vitamin D insufficiency is common in young Canadian women, and their vitamin D intake does not prevent it. Eur J Clin Nutr 2001; 55: 1091-1097.
208. Vieth R., Chan P. C., MacFarlane G. D. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001; 73: 288-294.
209. Stamp T. C. Factors in human vitamin D nutrition and in the production and cure of classical rickets. Proc Nutr Soc 1975; 34: 119-130.
210. Holick M. F. Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr 1995; 61: 638S-645S.
211. Webb A. R., Kline L., Holick M. F. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67: 373-378.
212. Wlaschek M., Tantcheva-Poor I., Naderi L., Ma W., Schneider L. A., Razi-Wolf Z. et al. Solar UV irradiation and dermal photoaging. J Photochem Photobiol B 2001; 63: 41-51.
213. Trautinger F. Mechanisms of photodamage of the skin and its functional consequences for skin ageing. Clin Exp Dermatol 2001; 26: 573-577.
214. Gocke E. Photochemical mutagenesis: examples and toxicological relevance. J Environ Pathol Toxicol Oncol 1902; 20: 285-292.
215. Bentham G. Association between incidence of non-Hodgkin's lymphoma and solar ultraviolet radiation in England and Wales. Br Med J 1996; 312: 1128-1131.
216. Green M. H., Petit-Frere C., Clingen P. H., Bentham G., Cole J., Arlett C. F. Possible effects of sunlight on human lymphocytes. J Epidemiol 1999; 9: S48-S57.
217. Scragg R., Khaw K. T., Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr 1995; 49: 640-646.
218. Portale A. A., Halloran B. P., Morris R. C. J. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 1989; 83: 1494-1499.
219. Zhang M. Y., Wang X., Wang J. T., Compagnone N. A., Mellon S. H., Olson J. L. et al. Dietary phosphorus transcriptionally regulates 25-hydroxyvitamin D-1alpha-hydroxylase gene expression in the proximal renal tubule. Endocrinology 2002; 143: 587-595.
220. Rodriguez M., Almaden Y., Hernandez A., Torres A. Effect of phosphate on the parathyroid gland: direct and indirect? Curr Opin Nephrol Hypertens 1996; 5: 321-328.
221. Hernandez A., Concepcion M. T., Rodriguez M., Salido E., Torres A. High phosphorus diet increases preproPTH mRNA independent of calcium and calcitriol in normal rats. Kidney Int 1996; 50: 1872-1878.
222. Wang Q., Paloyan E., Parfitt A. M. Phosphate administration increases both size and number of parathyroid cells in adult rats. Calcif Tissue Int 1996; 58: 40-44.
223. Canalejo A., Hernandez A., Almaden Y., Concepcion M. T., Felsenfeld A., Torres A. et al. The effect of a high phosphorus diet on the parathyroid cell cycle. Nephrol Dial Transplant 1998; 13(suppl. 3): 19-22.
224. Slatopolsky E., Dusso A., Brown A. J. The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. Am J Med Sci 1999; 317: 370-376.
225. Zemel M. B., Linkswiler H. M. Calcium metabolism in the young adult male as affected by level and form of phosphorus intake and level of calcium intake. J Nutr 1981; 111: 315-324.
226. Silverberg S. J., Shane E., Clemens T. L., Dempster D. W., Segre G. V., Lindsay R. et al. The effect of oral phosphate administration on major indices of skeletal metabolism in normal subjects. J Bone Miner Res 1986; 1: 383-388.
227. Calvo M. S., Kumar R., Heath H. Elevated secretion and action of serum parathyroid hormone in young adults consuming high phosphorus, low calcium diets assembled from common foods. J Clin Endocrinol Metab 1988; 66: 823-829.
228. Brixen K., Nielsen H. K., Charles P., Mosekilde L. Effects of a short course of oral phosphate treatment on serum parathyroid hormone (1-84) and biochemical markers of bone turnover: a dose-response study. Calcif Tissue Int 1992; 51: 276-281.
229. Karkkainen M., Lamberg-Allardt C. An acute intake of phosphate increases parathyroid hormone secretion and inhibits bone formation in young women. J Bone Miner Res 1996; 11: 1905-1912.
230. Levy Y., Bansal M., Zackson D. A., Lane J., Shike M. Phosphate depletion syndrome; case report with bone and muscle histology findings and review of the literature. JPEN J Parenter Enteral Nutr 1988; 12: 313-317.
231. Yates A. J., Oreffo R. O., Mayor K., Mundy G. R. Inhibition of bone resorption by inorganic phosphate is mediated by both reduced osteoclast formation and decreased activity of mature osteoclasts. J Bone Miner Res 1991; 6: 473-478.
232. Whybro A., Jagger H., Barker M., Eastell R. Phosphate supplementation in young men; lack of effect on calcium homeostasis and bone turnover. Eur J Clin Nutr 1998; 52: 29-33.
233. Calvo M. S. Dietary phosphorus, calcium metabolism and bone. J Nutr 1993; 123: 1627-1633.
234. Anderson J. J., Sell M. L., Garner S. C., Calvo M. S. Phosphorus. In: B. A. Bowman, R. M. Russell (eds). Present knowledge in nutrition, 8th Edn. Washington, DC: ILSI Press, 2001: 281-291.
235. Giovannucci E. Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 1998; 9: 567-582.
236. Resnick L. M., Nicholson J. P., Laragh J. H. Calcium metabolism in essential hypertension: relationship to altered renin system activity. Fed Proc 1986; 45: 2739-2745.
237. MacGregor G. A., Cappuccio F. P. The kidney and essential hypertension: a link to osteoporosis? J Hypertens 1993; 11: 781-785.
238. Allen L. H., Wood R. J. Calcium and phosphorus. In: M. E. Shils, J. A. Olson, M. Shike (eds). Modern nutrition in health and disease, 8th Edn. Philadelphia: Lea & Febiger, 1994: 144-163.
239. Urbano G., Lopez-Jurado M., Aranda P., Vidal-Valverde C., Tenorio E., Porres J. The role of phytic acid in legumes: antinutrient or beneficial function? J Physiol Biochem 2000; 56: 283-294.
240. de Oliveira A. C., Queiroz K. S., Helbig E., Reis S. M., Carraro F. The domestic processing of the common bean resulted in a reduction in the phytates and tannins antinutritional factors, in the starch content and in the raffinose, stachiose and verbascose flatulence factors. Arch Latinoam Nutr 2001; 51: 276-283.
241. Barsotti G., Morelli E., Cupisti A., Meola M., Dani L., Giovannetti S. A low-nitrogen low-phosphorus Vegan diet for patients with chronic renal failure. Nephron 1996; 74: 390-394.
242. Soroka N., Silverberg D. S., Greemland M., Birk Y., Blum M., Peer G. et al. Comparison of a vegetable-based (soya) and an animal-based low-protein diet in predialysis chronic renal failure patients. Nephron 1998; 79: 173-180.
243. Lumlertgul D., Burke T. J., Gillum D. M., Alfrey A. C., Harris D. C., Hammond W. S. et al. Phosphate depletion arrests progression of chronic renal failure independent of protein intake. Kidney Int 1986; 29: 658-666.
244. Campbell T. C., Junshi C. Diet and chronic degenerative diseases: perspectives from China. Am J Clin Nutr 1994; 59: 1153S-1161S.
245. McCarty M. F. Mortality from Western cancers rose dramatically among African-Americans during the 20th century: are dietary animal products to blame? Med Hypotheses 2001; 57: 169-174.
246. Sacks F. M., Rosner B., Kass E. H. Blood pressure in vegetarians. Am J Epidemiol 1974; 100: 390-398.
247. McDougall J., Litzau K., Haver E., Saunders V., Spiller G. A. Rapid reduction of serum cholesterol and blood pressure by a twelve-day, very low fat, strictly vegetarian diet. J Am Coll Nutr 1995; 14: 491-496.
248. Kjeldsen-Kragh J. Rheumatoid arthritis treated with vegetarian diets. Am J Clin Nutr 1999; 70: 594S-600S.
249. Hafstrom I., Ringertz B., Spangberg A., von Zweigbergk L., Brannemark S., Nylander I. et al. A vegan diet free of gluten improves the signs and symptoms of rheumatoid arthritis: the effects on arthritis correlate with a reduction in antibodies to food antigens. Rheumatology (Oxford) 2001; 40: 1175-1179.
250. Barnard N. Food for Life: How the New Four Food Groups Can Save your Life. New York: Crown, 1994.
251. McCarty M. F. Eating to Live - How a Low-fat, Low-salt, Whole-food Vegan Diet can Help You Stay Lean and Healthy into Ripe Old Age. Encinitas, CA: NutriGuard Research, 2002.
252. Wachman A., Bernstein D. S. Diet and osteoporosis. Lancet 1968; 1: 958-959.
253. Abelow B. J., Holford T. R., Insogna K. L. Cross-cultural association between dietary animal protein and hip fracture: a hypothesis. Calcif Tissue Int 1992; 50: 14-18.
254. Feskanich D., Willett W. C., Stampfer M. J., Colditz G. A. Protein consumption and bone fractures in women. Am J Epidemiol 1996; 143: 472-479.
255. Tucker K. L., Hannan M. T., Chen H., Cupples L. A., Wilson P. W., Kiel D. P. Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. Am J Clin Nutr 1999; 69: 727-736.
256. New S. A., Robins S. P., Campbell M. K., Martin J. C., Garton M. J., Bolton-Smith C. et al. Dietary influences on bone mass and bone metabolism: further evidence of a positive link between fruit and vegetable consumption and bone health? Am J Clin Nutr 2000; 71: 142-151.
257. Sellmeyer D. E., Stone K. L., Sebastian A., Cummings S. R. A high ratio of dietary animal to vegetable protein increases the rate of bone loss and the risk of fracture in postmenopausal women [In Process Citation]. Am J Clin Nutr 2001; 73: 118-122.
258. Calvo M. S., Park Y. K. Changing phosphorus content of the U.S. diet: potential for adverse effects on bone. J Nutr 1996; 126: 1168S-1180S.
259. Israel K. D., Michaelis O. E., Reiser S., Keeney M. Serum uric acid, inorganic phosphorus, and glutamic-oxalacetic transaminase and blood pressure in carbohydrate-sensitive adults consuming three different levels of sucrose. Ann Nutr Metab 1983; 27: 425-435.
260. Hallfrisch J., Ellwood K., Michaelis O. E., Reiser S., Prather E. S. Plasma fructose, uric acid, and inorganic phosphorus responses of hyperinsulinemic men fed fructose. J Am Coll Nutr 1986; 5: 61-68.
261. Giovannucci E., Rimm E. B., Wolk A., Ascherio A., Stampfer M. J., Colditz G. A. et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998; 58: 442-447.
262. Talamini R., Franceschi S., La Vecchia C., Serraino D., Barra S., Negri E. Diet and prostatic cancer: a case-control study in northern Italy. Nutr Cancer 1992; 18: 277-286.
263. Jain M. G., Hislop G. T., Howe G. R., Ghadirian P. Plant foods, antioxidants, and prostate cancer risk: findings from case-control studies in Canada. Nutr Cancer 1999; 34: 173-184.
264. Cohen J. H., Kristal A. R., Stanford J. L. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 2000; 92: 61-68.
265. Kolonel L. N., Hankin J. H., Whittemore A. S., Wu A. H., Gallagher R. P., Wilkens L. R. et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 2000; 9: 795-804.
266. Outila T. A., Karkkainen M. U., Seppanen R. H., Lamberg-Allardt C. J. Dietary intake of vitamin D in premenopausal, healthy vegans was insufficient to maintain concentrations of serum 25-hydroxyvitamin D and intact parathyroid hormone within normal ranges during the winter in Finland. J Am Diet Assoc 2000; 100: 434-441.
267. Lijnen P., Petrov V. Effect of oral calcium supplementation on intracellular calcium and plasma renin in men. J Endocrinol 1995; 146: 421-429.
268. Petrov V., Lijnen P. Modification of intracellular calcium and plasma renin by dietary calcium in men. Am J Hypertens 1999; 12: 1217-1224.
269. Burgess E. D., Hawkins R. G., Watanabe M. Interaction of 1,25-dihydroxy vitamin D and plasma renin activity in high renin essential hypertension. Am J Hypertens J1D-8803676 1990; 3: 903-905.
270. Park C. W., Oh Y. S., Shin Y. S., Kim C. M., Kim Y. S., Kim S. Y. et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73-81.
271. Kimura Y., Kawamura M., Owada M., Oshima T., Murooka M., Fujiwara T. et al. Effectiveness of 1,25-dihydroxyvitamin D supplementation on blood pressure reduction in a pseudohypoparathyroidism patient with high renin activity. Intern Med 1999; 38: 31-35.
272. Bucher H. C., Cook R. J., Guyatt G. H., Lang J. D., Cook D. J., Hatala R. et al. Effects of dietary calcium supplementation on blood pressure. A meta-analysis of randomized controlled trials. JAMA 1996; 275: 1016-1022.
273. Allender P. S., Cutler J. A., Follmann D., Cappuccio F. P., Pryer J., Elliott P. Dietary calcium and blood pressure: a meta-analysis of randomized clinical trials. Ann Intern Med 1996; 124: 825-831.
274. Garland C., Shekelle R. B., Barrett-Connor E., Criqui M. H., Rossof A. H., Paul O. Dietary vitamin D and calcium and risk of colorectal cancer a 19-year prospective study in men. Lancet 1985; 1: 307-309.
275. Slattery M. L., Sorenson A. W., Ford M. H. Dietary calcium intake as a mitigating factor in colon cancer. Am J Epidemiol 1988; 128: 504-514.
276. Bostick R. M., Potter J. D., Sellers T. A., McKenzie D. R., Kushi L. H., Folsom A. R. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. The Iowa Women's Health Study. Am J Epidemiol 1993; 137: 1302-1317.
277. Lipkin M., Newmark H. Calcium and the prevention of colon cancer. J Cell Biochem Suppl 1995; 22: 65-73.
278. Ghadirian P., Lacroix A., Maisonneuve P., Perret C., Potvin C., Gravel D. et al. Nutritional factors and colon carcinoma: a case-control study involving French Canadians in Montreal, Quebec, Canada. Cancer 1997; 80: 858-864.
279. La Vecchia C., Braga C., Negri E., Franceschi S., Russo A., Conti E. et al. Intake of selected micronutrients and risk of colorectal cancer. Int J Cancer 1997; 73: 525-530.
280. Sellers T. A., Bazyk A. E., Bostick R. M., Kushi L. H., Olson J. E., Anderson K. E. et al. Diet and risk of colon cancer in a large prospective study of older women: an analysis stratified on family history (Iowa, United States). Cancer Causes Control 1998; 9: 357-367.
281. Kampman E., Slattery M. L., Caan B., Potter J. D. Calcium, vitamin D, sunshine exposure, dairy products and colon cancer risk (United States). Cancer Causes Control 2000; 11: 459-466.
282. Chan J. M., Stampfer M. J., Ma J., Gann P. H., Gaziano J. M., Giovannucci E. L. Dairy products, calcium., and prostate cancer risk in the Physicians' Health Study. Am J Clin Nutr 2001; 74: 549-554.
283. Vlajinac H. D., Marinkovic J. M., Ilic M. D., Kocev N. I. Diet and prostate cancer: a case-control study. Eur J Cancer 1997; 33: 101-107.
284. Hayes R. B., Ziegler R. G., Gridley G., Swanson C., Greenberg R. S., Swanson G. M. et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 1999; 8: 25-34.
285. Schuurman A. G., van den Brandt P. A., Dorant E., Goldbohm R. A. Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study. Br J Cancer 1999; 80: 1107-1113.
286. Chan J. M., Pietinen P., Virtanen M., Malila N., Tangrea J., Albanes D. et al. Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland). Cancer Causes Control 2000; 11: 859-867.
287. Virtanen S. M., Laara E., Hypponen E., Reijonen H., Rasanen L., Aro A. et al. Cow's milk consumption, HLA-DQB1 genotype, and type 1 diabetes: a nested case-control study of siblings of children with diabetes. Childhood diabetes in Finland study group. Diabetes 2000; 49: 912-917.
288. Wasmuth H. E., Kolb H. Cow's milk and immune-mediated diabetes. Proc Nutr Soc 2000; 59: 573-579.
289. Cantorna M. T., Humpal-Winter J., DeLuca H. F. Dietary calcium is a major factor in 1,25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. J Nutr 1999; 129: 1966-1971.
290. Butcher J. The distribution of multiple sclerosis in relation to the dairy industry and milk consumption. N Z Med J 1976; 83: 427-430.
291. Malosse D., Perron H., Sasco A., Seigneurin J. M. Correlation between milk and dairy product consumption and multiple sclerosis prevalence: a worldwide study. Neuroepidemiology 1992; 11: 304-312.
292. Malosse D., Perron H. Correlation analysis between bovine populations, other farm animals, house pets, and multiple sclerosis prevalence. Neuroepidemiology 1993; 12: 15-27.